CAPR News and Press, Capricor Therapeutics Inc. From 02/01/24

Toronto, Ontario--(Newsfile Corp. - February 1, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce the appointment of Mr. Okunola Joshua Aina as its Chief Financial Officer, effective today. Mr. Aina is a senior finance and accounting professional wh...

-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing tra...

Toronto, Ontario--(Newsfile Corp. - January 22, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that it has entered into an amendment to its option agreement dated January 31 st , 2023 (the " Option Agreement ") setting out the terms of an option t...

Toronto, Ontario--(Newsfile Corp. - January 17, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce a second discovery of lithium-bearing zinnwaldite mineralization (" Area 2 ") in addition to the previously discussed Deer Pond Area within the east...

--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- ...

Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Caprock Mining Corp. (CSE: CAPR) ( "Caprock" or the "Company" ) is pleased to announce that following a comprehensive analysis by SGS Natural Resources ( "SGS" ) based in Lakefield, Ontario, the lithium-bearing mineral in samples col...

2023-11-14 20:30:05 ET Capricor Therapeutics, Inc. (CAPR) Q3 2023 Results Conference Call November 14, 2023 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin H...

2023-11-14 16:08:08 ET More on Capricor Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Capricor Therapeutics Q3 2023 Earnings Preview Capricor Therapeutics Q3 2...

-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution ...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...